Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.

Autor: Akhtar OS; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Szabo A; Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Bhatlapenumarthi V; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Forsberg M; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, New York, USA., Balev M; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., Patwari A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Cheruvalath H; Medical College of Wisconsin Medical School, Milwaukee, Wisconsin, USA., Bhutani D; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., Thanendrarajan S; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Dhakal B; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Zangari M; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Patel T; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Shrestha A; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Al-Hadidi S; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Cooper D; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, New York, USA., Lentzsch S; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., van Rhee F; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Shah MR; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Bag A; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., D'Souza A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Schinke C; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Chakraborty R; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., Shah N; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, New York, USA., Mohan M; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 1830-1834. Date of Electronic Publication: 2024 Aug 27.

Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation.

Autor: Akhtar OS; Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Research, Milwaukee, Wisconsin. Electronic address: oakhtar@mcw.edu., Arshad S; University of Kentucky College of Medicine, Lexington, Kentucky., Lian Q; Medical College of Wisconsin, Milwaukee, Wisconsin., Ahn KW; Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Research, Milwaukee, Wisconsin., D'Souza A; Medical College of Wisconsin, Milwaukee, Wisconsin., Dhakal B; Medical College of Wisconsin, Milwaukee, Wisconsin., Mohan M; Medical College of Wisconsin, Milwaukee, Wisconsin., Pasquini M; Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Research, Milwaukee, Wisconsin., Longo W; Medical College of Wisconsin, Milwaukee, Wisconsin., Shah NN; Medical College of Wisconsin, Milwaukee, Wisconsin., Fenske TS; Medical College of Wisconsin, Milwaukee, Wisconsin., Hamadani M; Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Research, Milwaukee, Wisconsin.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18.

Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.

Autor: Mohan M; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Van Oekelen O; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Akhtar OS; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Cohen A; Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Parekh S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Publikováno v: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting [Am Soc Clin Oncol Educ Book] 2024 Jun; Vol. 44 (3), pp. e432204.

Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis.

Autor: Akhtar OS; Medical College of Wisconsin, Milwaukee, WI, United States of America. Electronic address: oakhtar@mcw.edu., Sheeba BA; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America., Azad F; University at Buffalo Jacobs School of Medicine, Buffalo, NY, United States of America., Alessi L; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America., Hansen D; Moffitt Cancer Center, Tampa, FL, United States of America., Alsina M; Moffitt Cancer Center, Tampa, FL, United States of America., Baz R; Moffitt Cancer Center, Tampa, FL, United States of America., Shain K; Moffitt Cancer Center, Tampa, FL, United States of America., Grajales Cruz A; Moffitt Cancer Center, Tampa, FL, United States of America., Castaneda Puglianini O; Moffitt Cancer Center, Tampa, FL, United States of America., Liu H; Moffitt Cancer Center, Tampa, FL, United States of America., Blue B; Moffitt Cancer Center, Tampa, FL, United States of America., Nishihori T; Moffitt Cancer Center, Tampa, FL, United States of America., Al Jumayli M; Moffitt Cancer Center, Tampa, FL, United States of America., Extermann M; Moffitt Cancer Center, Tampa, FL, United States of America., Locke FL; Moffitt Cancer Center, Tampa, FL, United States of America., Mhaskar R; University of South Florida, Tampa, FL, United States of America., Freeman CL; Moffitt Cancer Center, Tampa, FL, United States of America.

Publikováno v: Journal of geriatric oncology [J Geriatr Oncol] 2024 Mar; Vol. 15 (2), pp. 101628. Date of Electronic Publication: 2023 Sep 16.

Quality of Care for Prostate Cancer in Kashmir, India: A Real-World Study.

Autor: Akhtar OS; Centre of Urology, Hakim Sanaullah Specialist Hospital and Cancer Centre, Sopore, IND., Andrabi SAR; Medical Oncology and Palliative Care, Dr. Shad Salim's Oncology Centre, Srinagar, IND., Bhat PS; Medical Oncology, Dr. Shad Salim's Oncology Centre, Srinagar, IND., Akhtar SS; Medical Oncology, Dr. Shad Salim's Oncology Centre, Srinagar, IND.; Medical Oncology, Hakim Sanaullah Specialist Hospital and Cancer Centre, Sopore, IND.

Publikováno v: Cureus [Cureus] 2023 Aug 15; Vol. 15 (8), pp. e43507. Date of Electronic Publication: 2023 Aug 15 (Print Publication: 2023).